AlphAIalphai — Financial news for AI agents
benzinga.comAUG 142 min read$CELC

Celcuity Analysts Slash Their Forecasts After Q2 Loss - Celcuity (NASDAQ:CELC)

Celcuity Inc (NASDAQ:CELC) reported a Q2 loss of $1.07 per share, narrower than the $1.17 consensus estimate, and down from a year-ago loss of 93 cents. Pre-market, shares rose 0.7% to $87.17. After the earnings release, Needham and Stifel kept Buy ratings but cut price targets to $140 and $150.

Original reporting
benzinga.com
Published Aug 14, 2026, 12:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 10:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$CELC
Neutral
medium confidence
Mentioned
$CELC
Relevance
6/10
alphai data visualization · based on benzinga.com
Decision brief

The 30-second read

$CELCNeutralMed
01

Why it matters

Traders may reassess the stock’s forward expectations because PTs were cut even though the loss per share came in better than expected.

02

Market read

Q2 EPS beat plus same-day PT cuts creates a mixed setup for CELC, supporting short-term trading but leaving direction dependent on forward details not provided here.

03

What to watch

The article does not include guidance, revenue trends, cash burn, or segment performance, which are typically the drivers behind PT reductions after an earnings beat.

Relevance 6/10Novelty 5/10Timing: pre-market today after Q2 results and same-day PT cuts

Background

Celcuity’s Q2 results were released with an EPS beat versus consensus, followed by sell-side price target reductions.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity reported a narrower-than-expected Q2 loss ($1.07 vs $1.17 consensus) and analysts cut price targets after the print.

Expected impact

Near-term volatility likely remains elevated as traders weigh the EPS beat against reduced PTs.

Evidence & confidence

The article provides the EPS beat and two specific PT cuts (Needham and Stifel), which can drive mixed sentiment and re-rate expectations.

Market effects

Sector

Limited. This is company-specific biotech/healthcare earnings with no broader sector policy or regulatory catalyst mentioned.

Regional

None indicated beyond US pre-market trading reaction.

Global

None indicated.

Counterpoint

What could challenge this read

The EPS beat could still dominate for momentum traders, and PT cuts may reflect conservative valuation rather than deteriorating fundamentals.

Key entities

  • company
    Celcuity Inc

    NASDAQ-listed company reporting Q2 results and receiving same-day analyst price target cuts.

  • analyst_firm
    Needham

    Maintained a Buy on CELC and lowered its price target from $157 to $140.

  • analyst_firm
    Stifel

    Maintained a Buy on CELC and cut its price target from $175 to $150.

Read at source← All news

Related articles

AUG 15
$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

yahoo.com5 min
AUG 13
$CELCMedAI 8/10

Celcuity Inc. (CELC): Results of Operations and Financial Condition

Celcuity Inc. (CELC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update • REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or meta

SEC EDGAR 8-K7 min
AUG 1
$CELCMed

Newly FDA-approved Revtorpyk wins NCCN listing

Celcuity (NASDAQ: CELC) said its Revtorpyk (gedatolisib) plus fulvestrant, with or without palbociclib, was added to NCCN Guidelines as a preferred Category 1 option for HR+, HER2- advanced or metastatic breast cancer after endocrine therapy progression. FDA approved Revtorpyk on July 14, 2026 for HR+/HER2- disease without detected PIK3CA mutation.

thepharmaletter.com4 min
JUL 24
$CELCMedAI 9/10

REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Breast Cancer, US

Celcuity’s REVTORPYK (gedatolisib) was approved by the US FDA in July 2026 for HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA wild-type, in combination with fulvestrant, with or without palbociclib, after progression on endocrine therapy. VIKTORIA-1 (n=392) showed arm A median PFS 9.3 vs 2.0 months for fulvestrant alone, ORR 32% vs 1%. Commercial launch planned for late Q3 2026.

clinicaltrialsarena.com6 min
JUL 23
$CELCMedAI 8/10

Celcuity faces securities fraud probe

Pomerantz LLP says it is investigating Celcuity Inc. for possible securities fraud after Celcuity announced a delayed commercial launch for its FDA-approved breast cancer drug Revtorpyk. The launch was pushed to late Q3 2026, later than analysts expected, and Celcuity shares fell 17.6% on July 15, 2026. The probe concerns whether the delay involved unlawful practices.

pluang.com3 min
JUL 22
$CELCMedAI 8/10

Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer

Celcuity (Nasdaq: CELC) said the FDA approved REVTORPYK (gedatolisib) with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after at least one endocrine therapy line. The VIKTORIA-1 data showed a progression-free survival benefit, with higher stomatitis, rash and metabolic side effects. The stock was reported down 17.4%.

simplywall.st6 min